Podcast series: Effective trial planning and design of Complex Innovative Design (CID) trials
Following on from the recommendations in the paper ‘Effective delivery of Complex Innovative Design (CID) cancer trials – a consensus statement’, the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by an experienced researcher, patient representative, statistician, ethic committee chair and member of the HRA.
The NIHR has existing podcasts around innovation in trial design and study delivery so we have joined forces to create a ‘playlist’ of podcasts aimed at anyone with an interest in working on or reviewing CID trials.
| Podcast Title | Summary | Speaker |
| Discussion on the definition of comoplex innovative trials | Discussion on the definition of complex innovative trials and the role of the Department of Health and Social Care | Emma Lowe, Department of Health and Social Care |
| What is a Complex Innovative Design trial and why do them? | Hear about what a Complex Innovative Design (CID) trial is and why we should do them. You'll hear examples of what is meant by a CID trial; the benefits of this method and the challenges they pose | Professor Pam Kearns, Cancer Research UK Clinical Trials Unit and Institute of Genomic Sciences in Birmingham |
| What is the role of the Data Monitoring Committee in Complex Innovative Design (CID) trials? | Hear about what a Data Monitoring Committee does, why it is important and how it makes decisions about clinical trials | Louise Brown, Medical Research Council Clinical Trials Unit at UCL |
| Transparency and publication of finished Complex Innovative Design (CID) trials arm data | Hear about the transparency and publication of data when an arm in a CID trial closes | Professor Pam Kearns, Cancer Research UK Clinical Trials Unit and Institute of Genomic Sciences in Birmingham |
| What information is important to patients and their families? | Hear about what information is important to patients and their families when considering taking part in a CID trial | Debbie Keatley, Independent Cancer Patients' Voice |
| What do Research Ethics Committee (REC) members need to know about CID trials? | Hear about what ethics committee members need to know from applicants about CID trials. | Stephanie Ellis, Chair of the Hampstead and Cambridge Central Ethics Committee |
| How to write patient facing documents that make sense | Hear about how to write patient facing documents that make sense. You'll hear recommendations on how information should be presented for patients and their family including the importance of considering the timing of sharing this information | Stephanie Ellis and Debbie Keatley |
| Complex Innovative Design Trials and Health Research Authority (HRA) Approval | Hear about Complex Innovative Design trials from the HRA's perspective | Will Navaie, Health Research Authority |
| The development of the consensus statement for the design and conduct of CID trials | Hear a discussion on the development of the paper for the British Journal of Cancer: 'Effective delivery of Complex Innovative Design(CID) cancer trials' | Professor Sarah Blagden, University of Oxford |
| Defining, designing and analysing CID trials | Hear a discussion on the statistical challenges and opportunities of defining, designing and analysing CID trials | Catey Bunce, King's College London |
| Defining a platform trial and the advantages of using a platform trial design | Hear a discussion around the definition of a platform trial in clinical oncology and its advantages | Professor David Sebag-Montefiore, University of Leeds |